Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Overweight rating on Immunovant (NASDAQ:IMVT) and raised the price target from $33 to $48.
September 27, 2023 | 11:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunovant's price target has been raised from $33 to $48 by Wells Fargo, which maintains an Overweight rating on the stock.
The raised price target and maintained Overweight rating by Wells Fargo indicates a positive outlook for Immunovant. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100